← Eichor
Study identifier: NCT07483827 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy

Condition: C3 Glomerulopathy (C3G) · Healthy Adult Participants  ·  Sponsor: eleva GmbH

PhasePhase 1
Planned participants39
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

This study is the first time the new medicine CPV-104 is being tested in people. CPV-104 is designed to regulate the complement system, which can be overactive in diseases such as C3 glomerulopathy (C3G), an ultra-rare kidney disorder. The study includes healthy adults and adult patients with C3G to assess safety, tolerability, how the body processes the medicine, and whether the immune system reacts to it. The study is divided in two part; in Part 1 (SAD), healthy volunteers receive one IV dose of CPV-104 or a placebo while in Part 2 (MAD) patients with C3G receive four weekly IV doses of CPV-104 (no placebo). Participants will have close monitoring, including side-effect checks, blood and urine tests, ECGs, vital signs, and blood samples to measure drug levels and antibodies. For those with C3G, researchers will also observe kidney function, although the main goal is safety, not testing effectiveness. A Safety Review Committee will regularly review results to ensure it is safe to continue to the next dose or study group.

This description comes directly from the study's public registry record.

Talk to the study team

Julia Flugel  ·  +49 761 470 990  ·  jflugel@elevabiologics.com

Daniela Wittmann  ·  +49 761 470 990  ·  dwittmann@elevabiologics.com

Always discuss trial participation with your own doctor first.

Locations (16)

Medizinische Universität WienVienna, AustriaRecruiting
Cliniques universitaires Saint-LucBrussels, BelgiumRecruiting
Fakultni Thomayerova nemocnicePrague, CzechiaRecruiting
Hôpital Européen Georges-Pompidou HEGPParis, FranceNot Yet Recruiting
Centre Hospitalier Universitaire De ToulouseToulouse, FranceRecruiting
Laiko General Hospital Of AthensAthens, GreeceRecruiting
Pauls Stradins Clinical University HospitalRiga, LatviaRecruiting
Vilnius University Hospital Santaros KlinikosVilnius, LithuaniaRecruiting
Amsterdam UMC StichtingAmsterdam, NetherlandsRecruiting
Hospital Curry Cabral - Centro Hospitalar de Lisboa Central - ULS Sao JoséLisbon, PortugalRecruiting
Fundacio PuigvertBarcelona, SpainNot Yet Recruiting
Hospital Universitario 12 De OctubreMadrid, SpainRecruiting

+ 4 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07483827